and Human Services (HHS)
EXPIRED
PILOT AND FEASIBILITY PROGRAM IN HUMAN ISLET BIOLOGY
RELEASE DATE: July 14, 2003
RFA: DK-03-021
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
(http://www.niddk.nih.gov)
CATALOG OF FEDERAL DOMESTIC ASSISTANCE NUMBER(S): 93.847
LETTER OF INTENT RECEIPT DATE: October 20, 2003 and June 20, 2004
APPLICATION RECEIPT DATES: November 20, 2003 and July 20, 2004
THIS RFA CONTAINS THE FOLLOWING INFORMATION
o Purpose of the RFA
o Research Objectives
o Mechanism(s) of Support
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Where to Send Inquiries
o Submitting an Application
o Peer Review Process
o Review Criteria
o Award Criteria
o Required Federal Citations
PURPOSE OF THIS RFA
Much of our understanding of the basic biology and function of the beta cell
and the pancreatic islet comes from studies of immortalized cell lines and
mouse tissue. However, differences in the general structure and organization
of mouse and human islets have been identified, and it remains uncertain if
these structural differences reflect functional differences as well. With
the variable success in islet transplantation and the inability to use in
vitro data to reliably predict islet engraftment and function, it is
important to learn all that we can about the structure, organization, and
signaling properties of human islets, and to compare and contrast these
findings with those reported with rodent models of islet function used to
date. The information gained from these studies should increase our ability
to develop new reagents for use in in vivo imaging studies of the human
islet, to develop fingerprinting assays for use in predicting human islet
transplant success, and to further develop cellular therapies for potential
use in the treatment of type 1 diabetes.
RESEARCH OBJECTIVES
Background
Over the last 5 years the NIDDK has supported a number of initiatives
designed to increase our basic knowledge of the development, structure, and
function of the pancreatic beta cell, with the ultimate goal of improving
treatment of diabetes and its complications.
In 2002, the NIDDK sponsored a workshop "Beta Cell Biology in the 21st
Century: Engineering a Pathway to Greater Understanding". An important goal
of the workshop was to identify areas of research opportunity in the adult
pancreatic beta cell. In 2003, an NIH advisory meeting focused on pancreatic
islet transplantation was also convened. Two research priorities that
emerged from these meetings were the need to obtain basic information about
the general architecture and organization of human islets, and to develop a
better functional definition of the characteristics of normal isolated human
beta cells and human beta cells in their natural milieu in the islet. To
date, much of the information generated has come from cell lines derived from
insulin-producing tumors (e.g., mouse and rat insulinomas, in modified
neuroendocrine cells (e.g., mouse AtT20 cells, with mouse and rat islets/beta
cells, and to a lesser degree from monkey islets. However, much of this
important basic information is lacking for human beta cells and human
pancreatic islets.
In an effort to increase our understanding of the pancreatic beta cell, NIDDK
has supported efforts to gather expression data from both mouse and human
beta cells, and to generate cell type-specific cDNA tools for the research
community. The Endocrine Pancreas Consortium Database
(http://www.cbil.upenn.edu/EPConDB) now contains information on the genes
expressed in cells of the pancreas identified by dbEST libraries from
pancreatic tissues including 12 mouse and 7 human libraries generated by the
Consortium. Microarray chips based on the collection of 13,910 human
pancreatic genes are presently being developed, and will be distributed in
2004. The information in this database, along with the cDNA reagents
generated, should aid researchers in pursuing novel lines of investigation in
the human beta cell.
Other recent initiatives of the NIDDK, the National Center for Research
Resources (NCRR), and the Juvenile Diabetes Research Foundation International
resulted in the establishment of multiple centers throughout the country that
isolate and distribute human islets for islet transplantation, clinical
studies aimed at improving cell viability and engraftment, and for basic
research purposes. To learn more about obtaining islets for basic research
purposes the coordinating center for the Islet Cell Resources may be
contacted (see http://www.infosci.coh.org/icr/).
Objectives and Scope
This program announcement is intended to stimulate research focusing on the
biology of human beta cells and human pancreatic islets. Examples that
illustrate possible areas of research are presented below. They are intended
only to provide a broad direction for research and should be considered
illustrative and not restrictive. Some potential topics are:
o Research on normal human pancreas structure including patterns of
innervation and blood flow, especially as these parameters relate to islet
structure, organization and function
o Studies of the distribution, numbers, and phenotypes of cells within the
endocrine tissue, endothelium, and ducts of the normal human pancreas
o Studies designed to investigate the life cycle of human beta cells focusing
on the roles of necrosis, apoptosis, and regeneration in controlling beta cell
mass
o Studies designed to determine surrogate markers of normal islet function or
dysfunction that could be ultimately used for evaluating transplantation
success
o Studies of the physiology and function of human islets, under defined
conditions designed to simulate pathophysiologic processes or the
transplantation setting
o Determine the transcriptional or protein profiles of purified or partially
purified populations of adult cell types from normal human pancreas
o Identify growth factors, extracellular matrix components, and/or signaling
molecules that may stimulate proliferation of functional adult beta cells
o Determine the cell surface and extracellular matrix components in the human
islet involved in cell-cell contact and in the organization of the islet
o Determine the morphology and function of islets following transplantation
into different locations in appropriate animal models
o Catalog and explore the function of newly identified proteins specific for
the beta cell. For example, determine their subcellular localization, their
interaction partners, and role in beta cell function in human islets
MECHANISM OF SUPPORT
This Program Announcement will use the NIH Exploratory/Development Research
Grant (R21) award mechanism
(see http://grants.nih.gov/grants/guide/pa-files/PA-03-107.html).
As an applicant, you will be solely responsible for planning, directing,
and executing the proposed project.
Applicants for the R21 must limit their requests to $250,000 direct costs per
year and are limited to two years. These R21 grants will not be renewable;
continuation of projects developed under this program will be through the
regular research grant (R01) program.
This RFA uses just-in-time concepts. It also uses the modular budgeting
format. (see http://grants.nih.gov/grants/funding/modular/modular.htm).
Specifically, if you are submitting an application with direct costs in each
year of $250,000 or less, use the modular format. This program does not
require cost sharing as defined in the current NIH Grants Policy Statement at
http://grants.nih.gov/grants/policy/nihgps_2001/part_i_1.htm.
FUNDS AVAILABLE
The NIDDK intends to commit approximately $2,000,000 in FY 2004 to fund 4 to
5 new grants, and approximately $2,000,000 in FY 2005 to fund 4 to 5 new
grants in response to this RFA. An applicant may request a project period of
up to 2 years and a budget for direct costs of up to $250,000 per year.
Because the nature and scope of the proposed research will vary from
application to application, it is anticipated that the size and duration of
each award will also vary. Although the financial plans of the NIDDK provide
support for this program, awards pursuant to this RFA are contingent upon the
availability of funds and the receipt of a sufficient number of meritorious
applications.
ELIGIBLE INSTITUTIONS
You may submit (an) application(s) if your institution has any of the
following characteristics:
o For-profit or non-profit organizations
o Public or private institutions, such as universities, colleges, hospitals,
and laboratories
o Units of State and Local governments
o Eligible agencies of the Federal government
o Domestic or foreign
INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS
Any individual with the skills, knowledge, and resources necessary to carry
out the proposed research is invited to work with their institution to
develop an application for support. Individuals from underrepresented racial
and ethnic groups as well as individuals with disabilities are always
encouraged to apply for NIH programs.
WHERE TO SEND INQUIRIES
We encourage your inquiries concerning this RFA and welcome the opportunity
to answer questions from potential applicants. Inquiries may fall into three
areas: scientific/research, peer review, and financial or grants management
issues:
o Direct your questions about scientific/research issues to:
Thomas Eggerman, M.D., Ph. D.
Islet Transplantation Program Director
Division of Diabetes, Endocrinology and Metabolism
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Boulevard, Room 697
Bethesda, MD 20892-5460
Telephone: (301) 594-8813
FAX: (301) 480-3503
E-mail: [email protected]
Carol Renfrew Haft, Ph.D.
Cell Biology Program Director
Division of Diabetes, Endocrinology and Metabolism
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Bouleveard, Room 605
Bethesda, MD 20892-5460
Telephone: (301) 594-7689
FAX: (301) 480-3503
E-mail: [email protected]
o Direct your questions about peer review issues to:
Francisco O. Calvo, Ph.D.
Chief, Review Branch
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Boulevard, Rm. 752
Bethesda, MD 20892-5452
(for express/courier service: Bethesda, MD 20817)
Telephone: (301) 594-8897
FAX: (301) 480-3505
Email: [email protected]
o Direct your questions about financial or grants management matters to:
Denise Payne
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Boulevard, Rm. 733
Bethesda, MD 20892-5456
Telephone: (301) 594-8845
FAX: (301) 480-3504
E-mail: [email protected]
LETTER OF INTENT
Prospective applicants are asked to submit a letter of intent that includes
the following information:
o Descriptive title of the proposed research
o Name, address, and telephone number of the Principal Investigator
o Names of other key personnel
o Participating institutions
o Number and title of this RFA
Although a letter of intent is not required, is not binding, and does not
enter into the review of a subsequent application, the information that it
contains allows NIDDK staff to estimate the potential review workload and
plan the review.
The letter of intent is to be sent one month prior to the application receipt
dates listed at the beginning of this document (e. g. October 20, 2003 or
June 20, 2004). The letter of intent should be sent to:
Chief, Review Branch
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Boulevard, Rm. 752
Bethesda, MD 20892-5452
(for express/courier service: Bethesda, MD 20817)
Telephone: (301) 594-8885
FAX: (301) 480-3505
SUBMITTING AN APPLICATION
Applications must be prepared using the PHS 398 research grant application
instructions and forms (rev. 5/2001). The PHS 398 is available at
http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive
format. For further assistance contact GrantsInfo, Telephone (301) 710-0267,
Email: [email protected].
SUPLEMENTAL INSTRUCTIONS: All application instructions outlined in the PHS
398 application kit are to be followed, with the following requirements for
R21 applications:
1. R21 applications will use the "MODULAR GRANT" and "JUST-IN-TIME"
concepts, with direct costs requested in $25,000 modules, up to the total
direct costs limit of $250,000 per year.
2. Although preliminary data are not required for an R21 application, they
may be included.
3. Sections a-d of the Research Plan of the R21 application may not exceed
15 pages, including tables and figures.
4. R21 appendix materials should be limited, as is consistent with the
exploratory nature of the R21 mechanism, and should not be used to circumvent
the page limit for the research plan. Copies of appendix material will only
be provided to the primary reviewers of the application and will not be
reproduced for wider distribution. The following materials may be included
in the appendix:
o Up to five publications, including manuscripts (submitted or accepted for
publication), abstracts, patents, or other printed materials directly
relevant to the project. These may be stapled as sets.
o Surveys, questionnaires, data collection instruments, and clinical
protocols. These may be stapled as sets.
o Original glossy photographs or color images of gels, micrographs, etc.,
provided that a photocopy (may be reduced in size) is also included within the
15 page limit of items a-d of the research plan.
APPLICATION RECEIPT DATES: Applications submitted in response to this Request
For Applications will be accepted on November 20, 2003, and July 20, 2004.
SPECIFIC INSTRUCTIONS FOR MODULAR GRANT APPLICATIONS: Applications requesting
up to $250,000 per year in direct costs must be submitted in a modular grant
format. The modular grant format simplifies the preparation of the budget in
these applications by limiting the level of budgetary detail. Applicants
request direct costs in $25,000 modules. Section C of the research grant
application instructions for the PHS 398 (rev. 5/2001) at
http://grants.nih.gov/grants/funding/phs398/phs398.html includes step-by-step
guidance for preparing modular grants. Additional information on modular
grants is available at
http://grants.nih.gov/grants/funding/modular/modular.htm.
USING THE RFA LABEL: The RFA label available in the PHS 398 (rev. 5/2001)
application form must be affixed to the bottom of the face page of the
application. Type the RFA number on the label. Failure to use this label
could result in delayed processing of the application such that it may not
reach the review committee in time for review. In addition, the RFA title
and number must be typed on line 2 of the face page of the application form
and the YES box must be marked. The RFA label is also available at:
http://grants.nih.gov/grants/funding/phs398/label-bk.pdf.
SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten original of
the application, including the Checklist, and three signed, photocopies, in
one package to:
Center For Scientific Review
National Institutes Of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710
Bethesda, MD 20817 (for express/courier service)
At the time of submission, two additional copies of the application and all
appendices must be sent to:
Chief, Review Branch
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
6707 Democracy Boulevard, Room 752
Bethesda, MD 20892-5452
(for express/courier service: Bethesda, MD 20817)
APPLICATION PROCESSING: Applications must be received on or before the
application receipt date listed in the heading of this RFA. If an
application is received after that date, it will be returned to the applicant
without review.
Although there is no immediate acknowledgement of the receipt of an
application, applicants are generally notified of the review and funding
assignment within 8 weeks.
The Center for Scientific Review (CSR) will not accept any application in
response to this RFA that is essentially the same as one currently pending
initial review, unless the applicant withdraws the pending application.
However, when a previously unfunded application, originally submitted as an
investigator-initiated application, is to be submitted in response to an RFA,
it is to be prepared as a NEW application. That is the application for the
RFA must not include an Introduction describing the changes and improvements
made, and the text must not be marked to indicate the changes. While the
investigator may still benefit from the previous review, the RFA application
is not to state explicitly how.
PEER REVIEW PROCESS
Upon receipt, applications will be reviewed for completeness by the CSR and
responsiveness by the NIDDK. Incomplete and/or non-responsive applications
will be returned to the applicant without further consideration.
Applications that are complete and responsive to the RFA will be evaluated
for scientific and technical merit by an appropriate peer review group
convened by the NIDDK in accordance with the review criteria stated below.
As part of the initial merit review, all applications will:
o Receive a written critique
o Undergo a selection process in which only those applications deemed to have
the highest scientific merit, generally the top half of applications under
review, will be discussed and assigned a priority score
o Receive a second level review by the National Diabetes and Digestive and
Kidney Diseases Advisory Council.
REVIEW CRITERIA
The goals of NIH-supported research are to advance our understanding of
biological systems, improve the control of disease, and enhance health. In
the written comments, reviewers will be asked to discuss the following
aspects of the application in order to judge the likelihood that the proposed
research will have a substantial impact on the pursuit of these goals:
o Significance
o Approach
o Innovation
o Investigator
o Environment
The scientific review group will address and consider each of these criteria,
specific to the objectives of the RFA, in assigning the application's overall
score, weighting them as appropriate for each application. The application
does not need to be strong in all categories to be judged likely to have major
scientific impact and thus deserve a high priority score. For example, an
investigator may propose to carry out important work that by its nature is not
innovative but is essential to move a field forward.
SIGNIFICANCE: Does this study address an important problem? If the aims of
the application are achieved, how will scientific knowledge be advanced? What
will be the effect of these studies on the concepts or methods that drive
this field?
APPROACH: Are the conceptual framework, design, methods, and analyses
adequately developed, well-integrated, and appropriate to the aims of the
project? Does the applicant acknowledge potential problem areas and consider
alternative tactics?
INNOVATION: Does the project employ novel concepts, approaches or methods?
Are the aims original and innovative? Does the project challenge existing
paradigms or develop new methodologies or technologies?
INVESTIGATOR: Is the investigator appropriately trained and well suited to
carry out this work? Is the work proposed appropriate to the experience level
of the principal investigator and other researchers (if any)?
ENVIRONMENT: Does the scientific environment in which the work will be done
contribute to the probability of success? Do the proposed experiments take
advantage of unique features of the scientific environment or employ useful
collaborative arrangements? Is there evidence of institutional support?
SPECIAL R21 REVIEW CRITERIA: The R21 exploratory/development grant is a
mechanism for supporting novel scientific ideas or new model systems, as well
as for supporting the development of tools and technologies that have the
potential to significantly advance our knowledge or the status of health-
related research. Because the research plan is limited to 15 pages, an R21
grant application need not have background material or preliminary
information as one might normally expect in an R01 application. Appropriate
justification for the proposed work can be provided through literature
citations, data from other sources, or, when available, from investigator-
generated data. Preliminary data are not required for these R21
applications.
ADDITIONAL REVIEW CRITERIA: Some of the responsive studies may be
descriptive in nature or hypothesis generating, rather than hypothesis
driven, and therefore the review criteria for innovation will have reduced
importance. In addition, preliminary data, especially data in the human
islet, is not a requirement.
PROTECTION OF HUMAN SUBJECTS FROM RESEARCH RISK: The involvement of human
subjects and protections from research risk relating to their participation
in the proposed research will be assessed. (See criteria included in the
section on Federal Citations, below).
INCLUSION OF WOMEN, MINORITIES AND CHILDREN IN RESEARCH: The adequacy of
plans to include subjects from both genders, all racial and ethnic groups
(and subgroups), and children as appropriate for the scientific goals of the
research. Plans for the recruitment and retention of subjects will also be
evaluated. (See Inclusion Criteria in the sections on Federal Citations,
below).
CARE AND USE OF VERTEBRATE ANIMALS IN RESEARCH: If vertebrate animals are to
be used in the project, the five items described under Section f of the PHS
398 research grant application instructions (rev. 5/2001) will be assessed.
ADDITIONAL CONSIDERATIONS
DATA SHARING: The adequacy of the proposed plan to share data.
BUDGET: The reasonableness of the proposed budget and the requested period
of support in relation to the proposed research.
RECEIPT AND REVIEW SCHEDULE
Letter of Intent Receipt Date: October 20, 2003 June 20, 2004
Application Receipt Date: November 20, 2003 July 20, 2004
Peer Review Date: March 2004 October 2004
Council Review: May 2004 February 2005
Earliest Anticipated Start Date:July 2004 March 2005
AWARD CRITERIA
Award criteria that will be used to make award decisions include:
o Scientific merit (as determined by peer review)
o Availability of funds
o Programmatic priorities.
REQUIRED FEDERAL CITATIONS
HUMAN SUBJECTS PROTECTION: Federal regulations (45CFR46) require that
applications and proposals involving human subjects must be evaluated with
reference to the risks to the subjects, the adequacy of protection against
these risks, the potential benefits of the research to the subjects and
others, and the importance of the knowledge gained or to be gained.
http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm
MONITORING PLAN AND DATA SAFETY AND MONITORING BOARD: Research components
involving Phase I and II clinical trials must include provisions for
assessment of patient eligibility and status, rigorous data management,
quality assurance, and auditing procedures. In addition, it is NIH policy
that all clinical trials require data and safety monitoring, with the method
and degree of monitoring being commensurate with the risks (NIH Policy for
Data Safety and Monitoring, NIH Guide for Grants and Contracts, June 12,
1998: http://grants.nih.gov/grants/guide/notice-files/not98-084.html).
INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH: It is the policy of
the NIH that women and members of minority groups and their sub-populations
must be included in all NIH-supported clinical research projects unless a
clear and compelling justification is provided indicating that inclusion is
inappropriate with respect to the health of the subjects or the purpose of the
research. This policy results from the NIH Revitalization Act of 1993 (Section
492B of Public Law 103-43).
All investigators proposing clinical research should read the "NIH Guidelines
for Inclusion of Women and Minorities as Subjects in Clinical Research -
Amended, October, 2001," published in the NIH Guide for Grants and Contracts
on October 9, 2001
(http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html);
a complete copy of the updated Guidelines are available at
http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm.
The amended policy incorporates: the use of an NIH definition of clinical
research; updated racial and ethnic categories in compliance with the new OMB
standards; clarification of language governing NIH-defined Phase III clinical
trials consistent with the new PHS Form 398; and updated roles and
responsibilities of NIH staff and the extramural community. The policy
continues to require for all NIH-defined Phase III clinical trials that: a)
all applications or proposals and/or protocols must provide a description of
plans to conduct analyses, as appropriate, to address differences by
sex/gender and/or racial/ethnic groups, including subgroups if applicable;
and b) investigators must report annual accrual and progress in conducting
analyses, as appropriate, by sex/gender and/or racial/ethnic group
differences.
INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS:
The NIH maintains a policy that children (i.e., individuals under the age of
21) must be included in all human subjects research, conducted or supported
by the NIH, unless there are scientific and ethical reasons not to include
them. This policy applies to all initial (Type 1) applications submitted for
receipt dates after October 1, 1998.
All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines" on the inclusion of children as participants in
research involving human subjects that is available at
http://grants.nih.gov/grants/funding/children/children.htm.
REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS: NIH policy
requires education on the protection of human subject participants for all
investigators submitting NIH proposals for research involving human subjects.
You will find this policy announcement in the NIH Guide for Grants and
Contracts Announcement, dated June 5, 2000, at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.
HUMAN EMBRYONIC STEM CELLS (hESC): Criteria for federal funding of research on
hESCs can be found at http://stemcells.nih.gov/index.asp and at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html. Only
research using hESC lines that are registered in the NIH Human Embryonic Stem
Cell Registry will be eligible for Federal funding (see http://escr.nih.gov).
It is the responsibility of the applicant to provide the official NIH
identifier(s) for the hESC line(s) to be used in the proposed research.
Applications that do not provide this information will be returned without
review.
PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT: The
Office of Management and Budget (OMB) Circular A-110 has been revised to
provide public access to research data through the Freedom of Information Act
(FOIA) under some circumstances. Data that are (1) first produced in a
project that is supported in whole or in part with Federal funds and (2) cited
publicly and officially by a Federal agency in support of an action that has
the force and effect of law (i.e., a regulation) may be accessed through FOIA.
It is important for applicants to understand the basic scope of this
amendment. NIH has provided guidance at
http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.
Applicants may wish to place data collected under this RFA in a public
archive, which can provide protections for the data and manage the
distribution for an indefinite period of time. If so, the application should
include a description of the archiving plan in the study design and include
information about this in the budget justification section of the
application. In addition, applicants should think about how to structure
informed consent statements and other human subjects procedures given the
potential for wider use of data collected under this award.
URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and proposals
for NIH funding must be self-contained within specified page limitations.
Unless otherwise specified in an NIH solicitation, Internet addresses (URLs)
should not be used to provide information necessary to the review because
reviewers are under no obligation to view the Internet sites. Furthermore,
we caution reviewers that their anonymity may be compromised when they
directly access an Internet site.
HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to
achieving the health promotion and disease prevention objectives of "Healthy
People 2010," a PHS-led national activity for setting priority areas. This PA
is related to one or more of the priority areas. Potential applicants may
obtain a copy of "Healthy People 2010" at http://www.healthypeople.gov/.
AUTHORITY AND REGULATIONS: This program is described in the Catalog of
Federal Domestic Assistance at http://www.cfda.gov/ and is not subject to the
intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency review. Awards are made under the authorization of Sections
301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284)
and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. All
awards are subject to the terms and conditions, cost principles, and other
considerations described in the NIH Grants Policy Statement. The NIH Grants
Policy Statement can be found at
http://grants.nih.gov/grants/policy/policy.htm
The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and discourage the use of all tobacco products. In addition,
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in
certain facilities (or in some cases, any portion of a facility) in which
regular or routine education, library, day care, health care, or early
childhood development services are provided to children. This is consistent
with the PHS mission to protect and advance the physical and mental health of
the American people.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® |
||||||